Cellectar Biosciences Files 8-K on Financials
Ticker: CLRB · Form: 8-K · Filed: Nov 18, 2024 · CIK: 1279704
| Field | Detail |
|---|---|
| Company | Cellectar Biosciences, Inc. (CLRB) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Cellectar Biosciences dropped an 8-K detailing financials and operations. Check it out.
AI Summary
Cellectar Biosciences, Inc. filed an 8-K on November 18, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing details the company's status as a Delaware corporation with its principal executive offices located in Florham Park, NJ.
Why It Matters
This filing provides investors with crucial updates on Cellectar Biosciences' financial health and operational performance, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any immediate or significant new risks.
Key Players & Entities
- Cellectar Biosciences, Inc. (company) — Registrant
- November 18, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Florham Park, NJ (location) — Address of principal executive offices
- NOVELOS THERAPEUTICS, INC. (company) — Former company name
- COMMON HORIZONS INC (company) — Former company name
FAQ
What specific financial information is being reported in this 8-K?
This 8-K filing pertains to Cellectar Biosciences, Inc.'s results of operations and financial condition, and includes financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 18, 2024.
What is Cellectar Biosciences, Inc.'s state of incorporation?
Cellectar Biosciences, Inc. is incorporated in Delaware.
Where are Cellectar Biosciences, Inc.'s principal executive offices located?
Cellectar Biosciences, Inc.'s principal executive offices are located at 100 Campus Drive, Florham Park, NJ, 07932.
Has Cellectar Biosciences, Inc. operated under any former names?
Yes, Cellectar Biosciences, Inc. was formerly known as NOVELOS THERAPEUTICS, INC. and COMMON HORIZONS INC.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-11-18 07:15:28
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB The Nasdaq Capital M
Filing Documents
- tm2428692d1_8k.htm (8-K) — 25KB
- tm2428692d1_ex99-1.htm (EX-99.1) — 81KB
- tm2428692d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-119941.txt ( ) — 289KB
- clrb-20241118.xsd (EX-101.SCH) — 3KB
- clrb-20241118_lab.xml (EX-101.LAB) — 33KB
- clrb-20241118_pre.xml (EX-101.PRE) — 22KB
- tm2428692d1_8k_htm.xml (XML) — 3KB
02
Item 2.02. Results of Operations and Financial Condition. On November 18, 2024, we issued a press release announcing our financial results for the quarter ended September 30, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Number Title 99.1 Press release dated November 18, 2024, titled "Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update" 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. Date: November 18, 2024 By: /s/ Chad J. Kolean Name: Chad J. Kolean Title: Chief Financial Officer